GLENMARK Intraday Analysis...

GLENMARK Share Price

Open 939.50 Change Price %
High 953.80 1 Day 14.75 1.58
Low 933.30 1 Week -6.65 -0.70
Close 946.50 1 Month 62.15 7.03
Volume 403082 1 Year 224.95 31.18
52 Week High 994.00
52 Week Low 715.45
GLENMARK Important Levels
Resistance 2 965.50
Resistance 1 957.67
Pivot 944.53
Support 1 935.33
Support 2 927.50
NSE INDIA Most Active Stocks
JPASSOCIAT 14.95 9.93%
HDFCBANK 1377.05 3.70%
IDEA 105.90 -1.81%
ICICIBANK 283.00 1.51%
SUZLON 16.95 -0.88%
UNITECH 5.90 0.85%
SBIN 269.35 -0.43%
GMRINFRA 14.35 2.50%
AXISBANK 489.10 -0.82%
SOUTHBANK 20.00 0.50%
More..
NSE INDIA Top Gainers Stocks
BANARBEADS 90.45 19.96%
PDPL 26.45 19.95%
ADHUNIK 8.60 19.44%
FCSSOFT 0.35 16.67%
TARMAT 50.85 16.10%
JPINFRATEC 11.10 15.03%
BLUECHIP 0.40 14.29%
CGCL 44.15 12.34%
BLKASHYAP 22.75 11.52%
IFBIND 618.25 11.46%
More..
NSE INDIA Top Losers Stocks
NBCC 175.10 -39.46%
RASOYPR 0.15 -25.00%
NAKODA 0.40 -11.11%
NTL 7.75 -9.36%
NTL 7.75 -9.36%
REISIXTEN 0.60 -7.69%
SPYL 0.65 -7.14%
UBHOLDINGS 27.50 -6.30%
KAUSHALYA 4.75 -5.94%
UVSL 0.80 -5.88%
More..

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

GLENMARK Technical Analysis 5
As on 17th Feb 2017 GLENMARK Share Price closed @ 946.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 864.76 & Strong Buy for SHORT-TERM with Stoploss of 907.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLENMARK Target for February
1st Target up-side 927.48
2nd Target up-side 951.05
3rd Target up-side 974.62
1st Target down-side 860.22
2nd Target down-side 836.65
3rd Target down-side 813.08
GLENMARK Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 59.39 Sideways
MFI (14) MFI is 71.43 Sideways
CCI (20) CCI is 55.46 Sideways
WILLIAM %R (14) William %R is -28.61 Sideways
ADX (14) ADX is 17.46 Range Bound
PSAR Stoploss For Long Buy 913.00
10 Day Avg Volume Traded -6.86 % Less then 10 Day Average Volume
GLENMARK Other Details
Segment EQ
Market Capital 68178259968.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.glenmarkpharma.com
GLENMARK Address
GLENMARK
Glenmark House
B D S Marg
Mumbai, 400099
India
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990
GLENMARK Latest News
Interactive Technical Analysis Chart Glenmark Pharmaceuticals Limited ( GLENMARK NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Glenmark Pharmaceuticals Limited
GLENMARK Business Profile
Glenmark Pharmaceuticals (GPL) is engaged in the research and development, manufacturing and marketing of branded formulations in India and abroad. The company is headquartered at Mumbai and was incorporated in the year 1977 by Gracias Saldanha. Its business segments include India API, exports formulations and API NCE research. The company is present in over 80 countries across the globe, with some of its subsidiaries and representative offices in the United States, the United Kingdom, Switzerland, Brazil, South Africa, Nigeria, Russia, Philippines and Malaysia. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API. Glenmark Pharmaceuticals` research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials. For the last five years the company has increased its growth through investment in dedicated research and development, including cutting-edge New Chemical Technology (NCE) research. The company currently ranks among the top 20 Indian pharmaceutical firms. The current market capitalization stands at Rs 13,855.67 crore. The company has reported a consolidated sales of Rs 1463.38 crore and a Net Profit of Rs 157.3 crore for the quarter ended September 2013. The company management includes Glenn Saldanha - Chairman & Managing Director, Rajesh V Desai - Executive Director & CFO, Cherylann Pinto - Director - Corporate Affairs, D R Mehta - Non Executive Director, Bernard Munos - Non Executive Director, J F Ribeiro - Non Executive Director, Brian W Tempest - Non Executive Director, Sridhar Gorthi - Non Executive Director, Hocine Sidi Said - Non Executive Director, N B Desai - Non Executive Director. The Registered office is at B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai,Maharashtra - 400026 and corporate office is at Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E, Mumbai - 400099 in MAHARASHTRA.